FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149196896> ?p ?o ?g. }

• W2149196896 endingPage "1516" @default.
• W2149196896 startingPage "1514" @default.
• W2149196896 abstract "Although considerable progress has been made in the treatment of inflammatory bowel disease (IBD), more than 75 % of patients with Crohn’s disease still require surgery at least once in their lifetime, usually for strictures and bowel obstruction. These often reflect intestinal fibrosis, a common histopathologic feature of IBD [1]. Although intestinal fibrosis is traditionally considered a consequence of excessive chronic inflammation, treatment with anti-tumor necrosis factor-α and other immunomodulatory drugs, which effectively ameliorate bowel inflammation, has unfortunately done little to curb the incidence of fibrotic complications. This observation has motivated investigators to reconsider the mechanisms that lead to intestinal fibrosis in an effort to identify alternative therapeutic approaches [2]. In this issue of Digestive Diseases and Sciences, Baird et al. [3] report on the anti-fibrotic potential of prostaglandin E2 (PGE2) and polyenylphosphatidylcholine (PPC).The initial glimmer of our current recognition that PGE2 is critical to the homeostasis of the gastrointestinal (GI) tract dates to 1938, when acetylsalicylic acid, or aspirin, was first reported to cause gastric hemorrhage [4], which in 1955 was attributed to its potential to promote erosive gastritis [5]. The roots of our mechanistic understanding for these observations derive from two Nobel Prize-winning discoveries, namely the purification and structural characterization of prostaglandins by Sune Bergstrom and Bengt Samuelsson, and the subsequent discovery by John Vane that aspirin inhibited the enzymatic production of prostaglandins. Today, it is recognized that abundant production of PGE2 by the constitutively active cyclooxygenase-1 in gastric epithelial cells is critical to their protection from a harsh acidic environment. It is now appreciated that PGE2 promotes epithelial integrity in other parts of the GI tract and indeed in other organs. That PGE2 protects against epithelial injury is evident from its anti-apoptotic effects in a mouse model of radiation colitis [6]. Although PGE2 is classically thought of as a pro-inflammatory molecule, this reputation largely reflects its actions on the microvasculature, but—interestingly—its effects on leukocytes are predominantly suppressive, as exemplified by its contribution to immune tolerance in the gut [7]. The increased risk of Crohn’s disease associated with the use of aspirin and other NSAIDs [8] may therefore be explained by the loss of both the anti-inflammatory and epithelial-protective actions of PGE2.Returning to the challenge of curbing fibrotic responses, significant data—mostly from studies of the lung, liver, kidney, and skin—support the hypothesis that PGE2 exerts anti-fibrotic effects independently of its anti-inflammatory and epithelial-protective actions. This reflects that PGE2 can also inhibit nearly all aspects of fibroblast activation via its ability to increase intracellular cyclic AMP [9]; in vivo administration of PGE2 can prevent lung fibrosis in mouse models [10]. The paper by Baird and colleagues reports for the first time that exogenous administration of PGE2 ameliorated intestinal fibrosis in the commonly employed 2,4,6-trinitrobenzene sulfonic acid (TNBS) murine model. The authors also examined the effects of PGE2 on intestinal fibroblasts in vitro, and like fibroblasts from other organs, PGE2 directly inhibited fibroblast proliferation and collagen production. Since in this in vivo study PGE2 was co-administered with TNBS, it inhibited intestinal inflammation as well. This experimental design, therefore, fails to distinguish whether PGE2 is capable of actually reversing preexisting intestinal fibrosis or whether it merely limits the inflammatory damage that culminates in fibrosis. As noted earlier, an independent anti-fibrotic effect is essential if we are to argue that PGE2 is superior to existing immunomodulatory drugs used to treat IBD. Although its recognized direct inhibitory effects on fibroblast functions would predict that this would be the case, a proof-of-principle experiment would require its administration later in the disease model when intestinal fibrosis is already established.What about PPC? PPC is a mixture of polyunsaturated phosphatidylcholine (PC) molecules derived from plant-based extracts that has primarily been used for the treatment of liver disease [11]. PC, an essential component of the lipid membrane bilayers of all cells, contributes to the integrity of the mucosal barrier of epithelial cells, including those lining the GI tract. The observation that mucosal PC content is diminished in patients with IBD [12] prompted early-stage clinical trials that suggest that exogenous PPC is potentially beneficial for IBD patients [13]. Baird and colleagues reported that PPC inhibited intestinal inflammation and fibrosis elicited by TNBS to the same degree as did PGE2, consistent with prior reports of the inhibitory effects of PPC on alcohol-induced cirrhosis in vivo [11] and on collagen synthesis by hepatic stellate fibroblast-like cells in vitro [14]. The parallel actions of PPC and PGE2 led to the hypothesis that the actions of PPC may be mediated by PGE2, which was not supported by the observation that colonic tissue concentrations of PGE2 did not increase with systemic administration of PPC. A more rigorous approach to this question might be to test whether the protective actions of PPC are abolished either by pharmacologic or genetic inhibition of PGE2 biosynthesis or by antagonism or deletion of its receptors. It is alternatively possible that PPC could initiate the production of other anti-inflammatory, anti-fibrotic eicosanoids that increase intracellular cyclic AMP (e.g., prostaglandin D2 or I2) that the authors did not measure. As was noted above for PGE2, addressing the question of whether PPC can attenuate intestinal fibrosis in this model independent of its effects on inflammation is also worthy of future study. Certainly, this work provides justification for additional exploration of PPC as potential therapy in IBD.While acknowledging the promise of PGE2 and PPC in treating intestinal fibrosis, questions and challenges still remain. In the study by Baird and colleagues, PGE2 was administered orally, which brings to mind an oral analog of PGE2, misoprostol (Cytotec®), which has long been available to protect the stomach from NSAID-induced injury but whose use is notably limited by accompanying diarrhea. A potential strategy to circumvent this limitation would be to take advantage of the functional specificity mediated by individual receptors for PGE2. There are four such E prostanoid receptors, termed EP1–EP4, with differing cellular distribution and signal transduction mechanisms; only EP2 and EP4 signal via increased cyclic AMP. Increases in intestinal motility are mediated by EP1 and EP3 [15], whereas a selective EP4 agonist protects against colitis manifestations in a mouse model while enhancing epithelial survival and regeneration [16]. Selective agonists of EP2 and/or EP4 may thus offer the promise of anti-inflammatory, epithelial-protective, and anti-fibrotic actions—ideal for IBD—without the unwanted side effects inherent to PGE2 itself or its receptor-nonselective analogs like misoprostol. One further possible challenge that might be anticipated is resistance to the beneficial effects of PGE2, as has been identified in other fibrotic disorders [17]. Finally, we would be remiss if we failed to acknowledge the well-recognized ability of PGE2 to promote tumorigenesis in the colon [18] and elsewhere—an important issue for IBD patients. It appears that several EP receptors may contribute to tumorigenesis at different stages of the disease. Therefore, a better understanding of whether and how the potential benefits of selective EP agonists can be harnessed without promoting tumor formation would be essential going forward. The question of whether PPC promotes tumorigenesis in this setting would also be important to answer. The promising results that Baird and colleagues present in this issue suggest that the answers to these questions are worth pursuing." @default.
• W2149196896 created "2016-06-24" @default.
• W2149196896 creator A5084604101 @default.
• W2149196896 creator A5088538395 @default.
• W2149196896 date "2015-04-24" @default.
• W2149196896 modified "2023-09-26" @default.
• W2149196896 title "Prostaglandin E2 and Polyenylphosphatidylcholine: Stiff Competition for the Fibrotic Complications of Inflammatory Bowel Disease?" @default.
• W2149196896 cites W1968537403 @default.
• W2149196896 cites W1978548274 @default.
• W2149196896 cites W1992825886 @default.
• W2149196896 cites W2000675841 @default.
• W2149196896 cites W2019307365 @default.
• W2149196896 cites W2030968860 @default.
• W2149196896 cites W2034936425 @default.
• W2149196896 cites W2052908465 @default.
• W2149196896 cites W2055533315 @default.
• W2149196896 cites W2057655488 @default.
• W2149196896 cites W2076709901 @default.
• W2149196896 cites W2078656023 @default.
• W2149196896 cites W2091539739 @default.
• W2149196896 cites W2101249156 @default.
• W2149196896 cites W2128575241 @default.
• W2149196896 cites W2135792508 @default.
• W2149196896 cites W2152625137 @default.
• W2149196896 cites W2171169752 @default.
• W2149196896 doi "https://doi.org/10.1007/s10620-015-3668-y" @default.
• W2149196896 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4830265" @default.
• W2149196896 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25902749" @default.
• W2149196896 hasPublicationYear "2015" @default.
• W2149196896 type Work @default.
• W2149196896 sameAs 2149196896 @default.
• W2149196896 citedByCount "0" @default.
• W2149196896 crossrefType "journal-article" @default.
• W2149196896 hasAuthorship W2149196896A5084604101 @default.
• W2149196896 hasAuthorship W2149196896A5088538395 @default.
• W2149196896 hasBestOaLocation W21491968961 @default.
• W2149196896 hasConcept C126322002 @default.
• W2149196896 hasConcept C2777198256 @default.
• W2149196896 hasConcept C2777956040 @default.
• W2149196896 hasConcept C2778260677 @default.
• W2149196896 hasConcept C2779134260 @default.
• W2149196896 hasConcept C2909339193 @default.
• W2149196896 hasConcept C41260117 @default.
• W2149196896 hasConcept C71924100 @default.
• W2149196896 hasConcept C90924648 @default.
• W2149196896 hasConceptScore W2149196896C126322002 @default.
• W2149196896 hasConceptScore W2149196896C2777198256 @default.
• W2149196896 hasConceptScore W2149196896C2777956040 @default.
• W2149196896 hasConceptScore W2149196896C2778260677 @default.
• W2149196896 hasConceptScore W2149196896C2779134260 @default.
• W2149196896 hasConceptScore W2149196896C2909339193 @default.
• W2149196896 hasConceptScore W2149196896C41260117 @default.
• W2149196896 hasConceptScore W2149196896C71924100 @default.
• W2149196896 hasConceptScore W2149196896C90924648 @default.
• W2149196896 hasIssue "6" @default.
• W2149196896 hasLocation W21491968961 @default.
• W2149196896 hasLocation W21491968962 @default.
• W2149196896 hasLocation W21491968963 @default.
• W2149196896 hasLocation W21491968964 @default.
• W2149196896 hasOpenAccess W2149196896 @default.
• W2149196896 hasPrimaryLocation W21491968961 @default.
• W2149196896 hasRelatedWork W1885482544 @default.
• W2149196896 hasRelatedWork W1982805001 @default.
• W2149196896 hasRelatedWork W2077257468 @default.
• W2149196896 hasRelatedWork W2149196896 @default.
• W2149196896 hasRelatedWork W2186523232 @default.
• W2149196896 hasRelatedWork W2689221540 @default.
• W2149196896 hasRelatedWork W2743022354 @default.
• W2149196896 hasRelatedWork W2946584236 @default.
• W2149196896 hasRelatedWork W2999965240 @default.
• W2149196896 hasRelatedWork W4362677971 @default.
• W2149196896 hasVolume "60" @default.
• W2149196896 isParatext "false" @default.
• W2149196896 isRetracted "false" @default.
• W2149196896 magId "2149196896" @default.
• W2149196896 workType "article" @default.